slide1 l.
Skip this Video
Loading SlideShow in 5 Seconds..
Biologicals: A Vision for the Future of Clinical Investigators in Evaluations of New Biological Products PowerPoint Presentation
Download Presentation
Biologicals: A Vision for the Future of Clinical Investigators in Evaluations of New Biological Products

Loading in 2 Seconds...

play fullscreen
1 / 15

Biologicals: A Vision for the Future of Clinical Investigators in Evaluations of New Biological Products - PowerPoint PPT Presentation

  • Uploaded on

Biologicals: A Vision for the Future of Clinical Investigators in Evaluations of New Biological Products. Karen Midthun, MD Acting Director Center for Biologics Evaluation And Research February 25, 2010. Add FDA Bar and . Diphtheria antitoxin from a milk horse named Jim

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

Biologicals: A Vision for the Future of Clinical Investigators in Evaluations of New Biological Products

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Biologicals:A Vision for the Future of Clinical Investigators in Evaluations of New Biological Products

Karen Midthun, MD

Acting Director

Center for Biologics Evaluation And Research

February 25, 2010

Add FDA Bar and

biologics control act 1902 the horse cber rode in on
Diphtheria antitoxin from a milk horse named Jim

1901: Anti-toxin from Jim was contaminated with tetanus

Serum made in St. Louis with no central or uniform controls to ensure potency and purity; no inspections

Serum bottled & used, resulting in the deaths of 13 children

Camden, NJ: 9 children died from tetanus-tainted smallpox vaccine

Biologics Control Act: government regulation of biologics; required licensure of products/facilities; authority to inspect and to withhold, suspend, or revoke licenses

Biologics Control Act, 1902The Horse CBER Rode in On

One of the first bottles (1895) of diphtheria antitoxin produced at the Hygienic Laboratory

biologics definition phs act section 351
Biologics – definition(PHS Act, section 351)
  • Virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component, or derivative, allergenic product, or analogous product …
  • Applicable to prevention, treatment, or cure of a disease or condition of human beings
products regulated by cber

Vaccines (preventive and therapeutic)

Blood Derivatives

Whole Blood


Blood Components

Selected Devices

Human Tissues

Xenotransplantation Products

Products Regulated by CBER



Somatic Cell & Gene Therapies

how are biologics different
Traditional drugs

Low molecular wgt. (<1 kDa)

Usually organic synthesis

Fewer critical process steps


Drug substance homogeneity

Maximal tolerated dose

Linear dose response

Usually more specific mechanisms of action

Usually metabolized

May have p450 interactions

Usually not immunogenic

Biological products

High molecular weight (>50 kDa)

Made with/from live cells/organisms

 inherent & contamination risk

Many critical process steps

Less well-characterized

Complex heterogeneous mixtures

Optimal biologic dose

Non-linear dose response

Multiple or even unknown

mechanisms of action


No P450 interactions

Often Immunogenic

How are Biologics Different?
clinical trial considerations vaccines for healthy children
Clinical Trial ConsiderationsVaccines for Healthy Children
  • Pivotal studies: typically large RCTs, e.g., several thousand to many thousand children (>70,000 infants in Rotateq rotavirus vaccine trial)
  • Control: typically placebo or active control (e.g., a licensed vaccine that may or may not be active against infectious disease of interest)
  • Live virus & bacterial vaccines or vectored vaccines assessed for shedding of the organisms (quantity & duration, risk of transmission to unvaccinated)
  • Adjuvants: vaccines may contain an adjuvant, need to evaluate safety and efficacy of vaccine as a whole
  • Vaccines intended for predominantly healthy populations, informs risk/benefit considerations
products for rare diseases use of flexible study designs
Products for Rare Diseases: Use of Flexible Study Designs
  • Historical controls sometimes used, e.g.,
    • Natural history of disease is well characterized & understood
  • Sequential trials
    • Early stopping for strong negative or positive cumulative data
  • Adaptive trials
    • Ongoing adjustments to treatment regimen, dosing, participant allocation, and/or sample size
  • Crossover trials
    • Study participants serve as own controls

Historical Safety IncidentsUnderscore need for control of manufacturing process, product testing, pre and post-market safety surveillance, proactive stance re EIDs

  • 1901:Contaminated diphtheria antitoxin lot  13 fatal tetanus cases; led to Biologics Control Act of 1902
  • 1955:Deficient viral inactivation (“Cutter incident”) - some lots of inactivated poliovirus vaccine  cases of poliomyelitis in >200 vaccinees and contacts
  • 1970's-’85:HIV transmitted through contaminated blood, blood components, and plasma derivatives; donor deferral and testing introduced, significantly reducing risk
  • 1990s:Variant Creutzfeldt-Jakob Disease (vCJD) recognized; risk-based donor deferral implemented; vCJD transmission by blood/blood products subsequentlyrecognized in UK
  • 1999:Intussusception after licensure of first rotavirus vaccine; led to vaccine withdrawal; very large safety studies conducted pre-licensure for subsequent rotavirus vaccines
complexity of manufacturing process gene therapy example



Retroviral vector

Multiple Cytokines and/or

Growth Factors

Allogeneic PBMC


Expressing New Gene



Fibronectin coated flasks

CD34+ transduction

Complexity of Manufacturing Process: gene therapy example
investigational gene therapy products potential risks and benefits
Investigational Gene Therapy ProductsPotential risks and benefits
  • Risk of detrimental inflammation:fatal hepatotoxicity in teenager after gene therapy trial for genetic enzyme deficiency using adenovirus vector (1999)
  • Risk of proliferation
    • 1st gene therapy trials for SCID-X1 w/o compatible stem cell donor (Europe)  T cell leukemia arose in 5/20 (construct integrated into a proto-oncogene regulating T cell proliferation - 1 died, 3 cured, 1 still being treated), BUT
    • Potential for cure: good immunity restored in 17/20 (for at least 5-8 years), 12/20 lost need for IV IgG (unusual after stem cell transplant), only 1/20 did not develop any T cells


cell scaffold products another group of complex biologicals
Cell Scaffold Products:Another Group of Complex Biologicals
  • Autologous or allogeneic cells on collagen or synthetic resorbable matrix for wound repair
  • Cell seeded scaffolds for cardiovascular repair
  • Encapsulated pancreatic islet cells
  • Expanded autologous cells on a matrix for collagen repair
investigational cellular therapy
Investigational Cellular Therapy

Example: Autologous stem cells (selected using monoclonal antibodies, expanded in culture, matured with cytokines, then given back to patient).

  • Potential risks oftherapy:
  • Tumorigenicity
  • Cellular contaminants
  • Adventitious agents
  • Safety of reagents
  • Sterility
  • Product stability
  • Product variability
  • Potential benefits of therapy:
  • Potential for much greater potency
  • Applicable to a wide range of very difficult to treat diseases
  • Potential for fewer adverse effects than conventional therapies
  • More targeted
investigational blood product
Investigational Blood Product


Example: Coagulation factors derived from either human plasma or culture media from genetically engineered cells for replacement therapy to treat patients with congenital deficiencies (e.g. hemophilia)

  • Potential Risks of Therapy:
  • Infections due to adventitious agents
  • Development of neutralizing antibodies due to modifications in the molecule
  • Allergic reactions to impurities
  • Potential Benefits of Therapy:
  • Effective in controlling bleeding episodes that are life threatening
consistency of manufacturing may vary by product
Consistency of manufacturing: may vary by product


Synthetic peptides can be manufactured with very high degrees of product consistency, but variability with autologous or allogeneic cellular products can be enormous (sometimes >100 fold)

  • Biologicals: diverse, complex products for the treatment and prevention of a broad range of common and rare diseases
  • Complex processes for manufacture, product testing, andfor evaluation of safety and efficacy
  • Include many products for healthy people–informs risk-benefit considerations
  • Include highly innovative products (great potential benefits but risks not fully defined)
  • Clinical trial designs may vary with product